A drug used to treat HIV-positive patients may offer gay and bisexual men some protection against contracting the virus, the authors of a new study say. Trials of the combination drug Truvada among nearly 2,500 men suggested it could reduce the chances of male-to-male HIV infection by 44%. Those using the drug regularly could further reduce the risk of infection, it was claimed. The study is published in the New England Journal of Medicine.
Truvada is the trade name of a drug manufactured by the California-based company Gilead Sciences Inc which combines two antiretroviral drugs, used to treat Aids. But this new study looks at whether it could be used to prevent HIV infection in the first place.
Almost 2,500 gay or bisexual men were randomly selected in Peru, Ecuador, Brazil, South Africa, Thailand and the United States. Half were given the pill, half were given dummy tablets. All the men were also given condoms and counselling on safe sex.
What the researchers found after about a year of testing was that the drug appeared to cut male-to-male HIV transmission by 44%, when the group taking the pill was compared with the placebo group.
Those who took the pill regularly were deemed to have reduced their risk of infection further, by up to 73%, and blood tests were run to confirm this relationship between pill-usage and protection levels.
The research was funded by the Bill & Melinda Gates Foundation, and the federal US body, the National Institute of Allergy and Infectious Diseases (NIAID). The pills were donated by their manufacturer.NIAID director, Dr Anthony Fauci, conceded more work needed to be done, but called the results impressive.
“This has been done in men who have sex with men. We need to know if we get similar results in women as well as in heterosexual men, which we have reason to believe we will,” he told the BBC. “We also need to get a long term view of were there any toxicities. We didn’t see anything that was significant but we need to follow that for a long period of time.”